PhaseRx, Inc. (PZRXQ)

Market Cap	12.00 -99.0%
Revenue (ttm)	n/a
Net Income	-13.89M
EPS	-1.19
Shares Out	11.71M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	438
Open	0.000001
Previous Close	n/a
Day's Range	0.000001 - 0.000001
52-Week Range	0.000001 - 0.0001
Beta	32.95
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About PhaseRx

PhaseRx, Inc., a biopharmaceutical company, engages in developing a portfolio of products for the treatment of inherited enzyme deficiencies in the liver using intracellular enzyme replacement therapy. The company develops its products based on its proprietary Hybrid mRNA technology platform, which allows the synthesis of missing enzyme inside the cell. Its therapeutic urea cycle disorder programs under development include PRX-OTC to treat ornithine transcarbamylase deficiency; PRX-ASL to treat argininosuccinate lyase deficiency; and PRX-ASS1 t...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2006
• Employees: 10
• Stock Exchange: OTCMKTS
• Ticker Symbol: PZRXQ

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Sep 5, 2026

Data Sources Report a data error